Disease · EFO_1001248

non-alcoholic fatty liver

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. non-alcoholic fatty liver. Diseases, record EFO_1001248. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001248

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: non-alcoholic fatty liver
Open Targets ID: EFO_1001248
Other names: MASLD, NAFL, NAFLD, NAFLD - nonalcoholic fatty liver disease, fatty liver disease, nonalcoholic, metabolic dysfunction-associated steatotic liver disease, non-alcoholic fatty liver disease, nonalcoholic fatty liver, nonalcoholic fatty liver disease
Highest stage of its drugs: Approval, for 2 of its 156 drugs, from EMA Human Drugs and FDA

Source Open Targets

Drugs156

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SEMAGLUTIDE	CHEMBL2108724	Protein	Approval	EMA Human Drugs	11	10	10	Drugs and targets
RESMETIROM	CHEMBL3261331	Small molecule	Approval	EMA Human Drugs and FDA	7	4	4	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
VITAMIN E	CHEMBL3989727		Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
EMPAGLIFLOZIN	CHEMBL2107830	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
PIOGLITAZONE	CHEMBL595	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
SAROGLITAZAR	CHEMBL4297530	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
DOCONEXENT	CHEMBL367149	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 156

See all 156 drugs

Targets148

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GLP1R	Glucagon-like peptide 1 receptor	9	Glucagon-like peptide 1 receptor agonist	Approval	https://conductscience.org/library/genes/2740	Drugs and targets
GCGR	Glucagon receptor	5	Glucagon receptor agonist	Phase 2	https://conductscience.org/library/genes/2642	Drugs and targets
NR1H4	Bile acid receptor	5	Bile acid receptor FXR agonist	Phase 2	https://conductscience.org/library/genes/9971	Drugs and targets
PPARA	Peroxisome proliferator-activated receptor	5	Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor alpha agonist	Phase 3	https://conductscience.org/library/genes/5465	Drugs and targets
PPARG	Peroxisome proliferator-activated receptor	5	Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor gamma modulator	Phase 3	https://conductscience.org/library/genes/5468	Drugs and targets
AR	Androgen receptor	3	Androgen Receptor agonist; Androgen Receptor antagonist	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets
FGF1	FGF1/KLB	3	FGF1/KLB activator; FGF1/KLB agonist	Phase 2	https://conductscience.org/library/genes/2246	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	3	HMG-CoA reductase inhibitor	Unknown	https://conductscience.org/library/genes/3156	Drugs and targets
KLB	FGF1/KLB	3	FGF1/KLB activator; FGF1/KLB agonist; FGFR4-KLB activator	Phase 2	https://conductscience.org/library/genes/152831	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	3	Sodium/glucose cotransporter 2 inhibitor	Phase 3	https://conductscience.org/library/genes/6524	Drugs and targets

1 to 10 of 148

See all 148 targets

Trials200

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02970942	Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.	Phase 2	320	2021-04-21	Hepatobiliary Disorders, Non-alcoholic Steatohepatitis	SEMAGLUTIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03248882	Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)	Phase 2	305	2020-03-10	Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis	CLESACOSTAT	Its record names the disease	ClinicalTrials.gov
NCT01265498	The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)	Phase 2	283	2015-08-21	Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)	OBETICHOLIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01694849	Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)	Phase 2	275	2022-11-03	Non-Alcoholic Steatohepatitis (NASH)	ELAFIBRANOR	Its record names the disease	ClinicalTrials.gov
NCT02279524	A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH	Phase 2	247	2021-07-14	Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses	ICOMIDOCHOLIC ACID	Open Targets' reading of its record	ClinicalTrials.gov
NCT02279407	A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients	Phase 2	223	2017-01-27	T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)	DAPAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT02781584	Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)	Phase 2	220	2022-02-02	Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)	CILOFEXOR, FENOFIBRATE, FIRSOCOSTAT, ICOSAPENT ETHYL, SELONSERTIB	Its record names the disease	ClinicalTrials.gov
NCT04198805	Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)	Phase 2	205	2023-05-25	Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis	DOCONEXENT, VITAMIN E	Its record names the disease	ClinicalTrials.gov
NCT02413372	A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)	Phase 2	184	2020-01-28	Non-Alcoholic Steatohepatitis	PEGBELFERMIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00063635	Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)	Phase 3	173	2012-09-27	Fatty Liver	METFORMIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 200

See all 200 trials

Comparisons in its trials60

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Obeticholic Acid vs Placebo: serious adverse events	13 of 141	10 of 142	283	NCT01265498	Trial comparisons
Obeticholic Acid vs Placebo: Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)	50 of 110	23 of 109	219	NCT01265498	Trial comparisons
Obeticholic Acid vs Placebo: Steatosis: Patients With Improvement	62 of 102	37 of 98	200	NCT01265498	Trial comparisons
Obeticholic Acid vs Placebo: Hepatocellular Ballooning: Patients With Improvement	47 of 102	30 of 98	200	NCT01265498	Trial comparisons
Obeticholic Acid vs Placebo: Lobular Inflammation: Patients With Improvement	54 of 102	34 of 98	200	NCT01265498	Trial comparisons
Obeticholic Acid vs Placebo: Portal Inflammation: Patients With Improvement	12 of 102	13 of 98	200	NCT01265498	Trial comparisons
Obeticholic Acid vs Placebo: Fibrosis: Patient With Improvement	36 of 102	19 of 98	200	NCT01265498	Trial comparisons
Obeticholic Acid vs Placebo: Resolution of NASH Diagnosis	22 of 102	13 of 98	200	NCT01265498	Trial comparisons
DR Cysteamine Bitartrate Capsule vs DR Cysteamine Bitartrate Placebo: Portal Inflammation: Patients With Improvement	18 of 88	14 of 81	169	NCT01529268	Trial comparisons
DR Cysteamine Bitartrate Capsule vs DR Cysteamine Bitartrate Placebo: Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)	25 of 88	18 of 81	169	NCT01529268	Trial comparisons

1 to 10 of 60

See all 60 comparisons in its trials

Papers from its trials156

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37355043	RESULT	1	PubMed
36847136	RESULT	1	PubMed
35439567	RESULT	1	PubMed
34909677	RESULT	1	PubMed
34887111	RESULT	1	PubMed
34570916	RESULT	1	PubMed
33811367	RESULT	1	PubMed
33185364	RESULT	2	PubMed
31611038	RESULT	1	PubMed
29805116	RESULT	1	PubMed

1 to 10 of 156

See all 156 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001248

GET https://conductscience.org/api/diseases/v1/EFO_1001248/drugs?page=2

API reference For AI assistants